01:30:01 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-04-22 Ordinarie utdelning DANCAN 0.00 DKK
2024-02-29 Bokslutskommuniké 2023
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-04-19 Ordinarie utdelning DANCAN 0.00 DKK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-04 Kvartalsrapport 2022-Q3
2022-09-20 Extra Bolagsstämma 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-04-08 Ordinarie utdelning DANCAN 0.00 DKK
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020


ListaSpotlight DK
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbolag. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.
2022-09-22 13:00:00

COPENHAGEN, Denmark, September 22, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma", "DCP" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has been granted proper authorization and flexibility to carry out the proposed Rights Issue at the Extraordinary General Meeting ("EGM") held September 20, 2022. At the EGM the Board of Directors also appointed Alexander Schoeneck and Jeppe Krog Rasmussen to the Board of Directors.

The Company held an EGM this week with the purpose of authorizing DanCann Pharma to carry out the proposed Rights Issue. This authorization was granted at the EGM. Furthermore, it was decided to appoint Jeppe Krog Rasmussen and Alexander Schoeneck to the DanCann Pharma Board of Directors as proposed. At the EGM Per Wester (Board Member) and Magnus Østergaard Dahlmann (Board Member) resigned from the Board of Directors, where Jeppe Krog Rasmussen and Alexander Schoeneck stepped in.

Magnus Østergaard Dahlmann (Board Member), comments:

- From the very beginning in 2018, it has been a great pleasure and a privilege for me to follow DanCann's start-up - and in recent years on the Board of Directors to help build the bridge to what is today DanCann Pharma A/S. For health reasons I have previously indicated that I would like to retire from Board of Directors work on a suitable occasion. Now that the opportunity presents itself, I have chosen to step back from the Board of Directors. I am convinced that the appointments of Alexander Schoeneck and Jeppe Krog Rasmussen to the Board of Directors will be of great strength for DanCann Pharma. 

Per Wester (Board Member), comments:

- We have been on an absolutely amazing trip together and I wish to thank every one of you for allowing me to be a part of this journey. Jeppe, you are a great entrepreneur. In the years I have had the pleasure of working with you, you have developed insanely fast. Take good care of your new insights. I wish DanCann Pharma and its employees and shareholders all the best in the future, I will follow you closely.

Carsten Trads (Chairman of the Board at DanCann Pharma), comments:

- It has been a privilege to have Magnus and Per onboard on our growth journey. It is hard to believe how much we have achieved in just 3-4 years together and your contribution has been massive. I hope that you will continue to be the fantastic ambassadors - as you are - for DanCann Pharma, both locally, nationally, and internationally. You have added professional touches to our organization - at the Board and as mentors for the management - and have been important bricks in establishing our solid foundation. Thank you for everything.

- At the same time, I am very happy to be able to welcome our two new board members. Jeppe Krog Rasmussen has previously been a member of the Board of Directors, whereas Alexander Schoeneck is new in this position. Both offer a lot of relevant experience to the Board through their backgrounds in corporate financing and investments and their thorough knowledge of DanCann Pharma and our history. We are looking forward to our co-operation.

Magnus Østergaard Dahlmann and Per Wester leave the Company as good leavers, and therefore retain their current warrants which are vested (25,000 warrants), and the remaining 50,000 warrants will withdrawal as these have not yet been vested.

About Jeppe Krog Rasmussen

Born in 1995. Founder and Chief Executive Officer (CEO) in DanCann Pharma A/S since the Company's foundation back in March 2018. Jeppe Krog Rasmussen is responsible for the strategic direction and operational execution of all processes relevant to DanCann Pharma. He was a member of the Company's Board of Directors during the years 2020-2022. Jeppe Krog Rasmussen is a serial entrepreneur with strong experience from starting and building companies as well as working and investing in complex industries. In addition to DanCann Pharma Jeppe Krog Rasmussen runs his investment company, XIGNOTUS CAPITAL ApS, where he manages his investment portfolio.

About Alexander Schoeneck

Born in 1983. Professional investor since 2016. Alexander Schoeneck is the chairman of the board in JEQ Capital, a fund with focus on small companies in an early stage. Alexander is also a board member in Corpura Fondkommission, EllWee AB (listed on Nasdaq First North), JEQ Capital Holding, Corpura Holding, Campingstugan Invest, Black Lion Media Group AB, Glassaparken AB and JJV Invest AB. Alexander has been part of DanCann Pharma's journey from the beginning and has always worked as an advisor for founder and CEO Jeppe Krog Rasmussen. Alexander has great experience when it comes to the financial markets, corporate finance and investor relations.

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com


Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.